Nature:一种能杀灭persister 休眠细胞的抗生素

2013-11-28 Nature中文网 Nature中文网

细菌药物反应的双重性质使人们更加担心今天的抗生素应对未来感染的能力。 一些细菌会形成遗传抗性,而其他的则会通过形成被称为 “persister”的休眠细胞(在这种细胞中抗生素的酶目标是失活的)而变得具有耐受性,能够在抗生素存在下存活。 Kim Lewis及同事进行了搜寻有可能通过破坏这些能量有限的细胞内的目标来杀灭persister 细胞的药物的研究工作。他们发现,acyldepsipepti

细菌药物反应的双重性质使人们更加担心今天的抗生素应对未来感染的能力。

一些细菌会形成遗传抗性,而其他的则会通过形成被称为 “persister”的休眠细胞(在这种细胞中抗生素的酶目标是失活的)而变得具有耐受性,能够在抗生素存在下存活。

Kim Lewis及同事进行了搜寻有可能通过破坏这些能量有限的细胞内的目标来杀灭persister 细胞的药物的研究工作。他们发现,acyldepsipeptide抗生素ADEP4能激发ClpP蛋白酶和细胞的蛋白水解机制,通过迫使persister 细胞降解一系列细胞蛋白来杀灭它们。


这是一个有潜在重要性的结果,它表明:将ADEP4这样的药物与传统抗生素相结合,有可能为慢性感染的控制提供新的可靠策略。

原文出处:

Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K.Activated ClpP kills persisters and eradicates a chronic biofilm infection.Nature. 2013 Nov 21;503(7476):365-70. doi: 10.1038/nature12790. 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879765, encodeId=e72318e976583, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 22 06:07:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725550, encodeId=82da1e2555043, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 21 15:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878070, encodeId=f8fb18e80705f, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 19 12:07:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668049, encodeId=dae1166804933, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Mon Sep 29 14:07:00 CST 2014, time=2014-09-29, status=1, ipAttribution=)]
    2014-06-22 柳叶一刀
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879765, encodeId=e72318e976583, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 22 06:07:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725550, encodeId=82da1e2555043, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 21 15:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878070, encodeId=f8fb18e80705f, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 19 12:07:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668049, encodeId=dae1166804933, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Mon Sep 29 14:07:00 CST 2014, time=2014-09-29, status=1, ipAttribution=)]
    2014-07-21 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879765, encodeId=e72318e976583, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 22 06:07:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725550, encodeId=82da1e2555043, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 21 15:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878070, encodeId=f8fb18e80705f, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 19 12:07:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668049, encodeId=dae1166804933, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Mon Sep 29 14:07:00 CST 2014, time=2014-09-29, status=1, ipAttribution=)]
    2014-02-19 anminleiryan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879765, encodeId=e72318e976583, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Jun 22 06:07:00 CST 2014, time=2014-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725550, encodeId=82da1e2555043, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jul 21 15:07:00 CST 2014, time=2014-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878070, encodeId=f8fb18e80705f, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Feb 19 12:07:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668049, encodeId=dae1166804933, content=<a href='/topic/show?id=902125e1351' target=_blank style='color:#2F92EE;'>#休眠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25713, encryptionId=902125e1351, topicName=休眠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34e226239625, createdName=yese, createdTime=Mon Sep 29 14:07:00 CST 2014, time=2014-09-29, status=1, ipAttribution=)]
    2014-09-29 yese

相关资讯

美报告称耐药菌每年夺去2.3万人生命

实验室显微镜下的抗碳青霉烯肠杆菌,其对最强的抗菌素也有抵抗性。 据美国中文网9月16日报道,美国联邦官员发布16日报告,称全美每年有230万人感染抗药性病菌,其中2.3万人被“超级病菌”夺命。而这其中最大的杀手就是顽固性梭菌(C. difficile)。报告同时指出,医生几十年来都在警告不要滥用抗菌素,但全美超过一半抗菌素处方药都是不必要的,滥用抗菌素造成“超级病菌

CHEST:短程抗生素治疗对VAP患者有效

为比较短期与长期抗生素治疗对呼吸机相关性肺炎(VAP)的治疗效果,来自希腊雅典attikon大学医院重症监护科的Dimitrios K. matthaiou博士及其同事进行了一项研究,研究结果在线发表于2013年6月20日的CHEST杂志上。研究显示:短程抗生素治疗与VAP患者更多的无抗生素日数相关。长疗程患者的复发率有明显降低趋势,但其与短疗程者在死亡率和复发率方面并无显著性

欧洲药管局否决Delamanid上市许可

近日,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)投票否决了Delamanid的上市许可。 Delamanid是一种用于多重耐药性肺结核(至少对异烟肼和利福平耐药的肺结核)患者的抗生素,可与其他药物联合使用。该药能对结核杆菌细胞壁的主要成分甲氧基及酮基分枝菌酸进行干扰,但其真正的作用机制尚不清楚。 此次EMA的否决决定是基于一项有481名多重耐药性肺结核患者参与的初步临床研究

Diabetes Care:抗生素是糖尿病足骨髓炎的治疗**

西班牙一项研究发现,对于糖尿病足骨髓炎和前足部溃疡患者,抗生素治疗是合理的首选。研究结果在线发表于10月15日《糖尿病护理》杂志。这是首个比较使用抗生素与手术治疗糖尿病足骨髓炎的研究,结果显示,2种治疗方法的愈合率、愈合时间和短期并发症相似。研究人员认为,该研究为糖尿病足医生提供了非常有用的信息,当患者有软组织感染伴有骨髓炎,如果有良好的血管供应,溃疡不会深到见骨,此时最好的治疗选择是使用抗生素9

法国拟试行按剂量出售抗生素

据法国《欧洲时报》10月29日报道,法国卫生部长图雷纳女士9月份宣布,为了减少药品浪费,将试行按剂量单位出售抗生素措施。现在,这条措施即将在志愿药房里试行三年。 据《费加罗报》报道,法国国民议会25日表决通过了志愿试行的药房三年当中试行按剂量单位销售抗生素决议。 卫生部长希望借此减少病人自我医疗现象,同时减少药品浪费现象。据统计,法国二分之一的报销药品都不曾服用,每个法国人自家小药房里

Lancet :网络培训有助控制对急性呼吸道感染的抗生素处方率

在初级保健医疗场所中大量开具抗生素处方,是抗生素耐药性的主要原因。10月发表在Lancet的一项研究评估了在多个医疗保健系统中,是否可以通过基于互联网培训模式改变开处方习惯。结果表明,网络培训跨越了语言与文化界限,在降低呼吸道感染抗生素处方率方面起到了重要作用。 背景:在初级保健医疗中大量应用抗生素,是导致产生抗生素耐药性的主要原因。医生和患者的教育程度会降低处方率,但主要依赖于工作人员的训练有